Diseases characterized by oxidative stress and chronic inflammation, such as cancer, cardiovascular disease, and neurodegenerative disorders, have garnered significant interest as potential therapeutic targets, including those aimed at activating NRF2 [3,4]. The gene discussed is NFE2L2; the disease is cancer.